Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.

January 3, 2012 updated by: Takeda

A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Pioglitazone Compared to Placebo on Bone Metabolism in Impaired Fasting Glucose, Postmenopausal Women for One Year of Treatment

The purpose of this study is to evaluate the effect of pioglitazone on bone metabolism in postmenopausal women with impaired fasting glucose.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The World Health Organization has estimated that 30% of all women aged over 50 years (postmenopausal) have osteoporosis according to a definition of Bone Mineral Density at any site being more than 2.5 standard deviations below the mean for young healthy adult women.

A known risk factor for development of osteoporosis and fracture is diabetes mellitus, with correlations to duration of disease and poor glycemic control.

Pioglitazone is a thiazolidinedione developed by Takeda Pharmaceuticals for the treatment of type 2 diabetes. Preclinical studies to date on the bone effects of thiazolidinediones have not clearly identified a mechanism of bone loss. While there is evidence of increased bone fractures in postmenopausal diabetic females treated with a thiazolidinedione, the mechanism is not known. Initial studies with thiazolidinediones in humans have focused on short term exposure (12 to 14 weeks) and non-diabetic females. These studies have shown acute changes in circulating bone markers and bone density, but have been questioned because they may not represent bone metabolism in states of abnormal glucose metabolism. Impaired glucose tolerance has been identified not only as a risk factor for developing type 2 diabetes, but also at higher risk for known complications of diabetes. Examination of the effect of thiazolidinediones on bone metabolism in IGT patients will provide data in patients with abnormal glucose tolerance, but without the potential confounding effects of oral hypoglycemic medications to treat type 2 diabetes.

The primary objective of this study is to evaluate the effect of pioglitazone on bone mass and metabolism in postmenopausal women with impaired fasting glucose or impaired glucose tolerance. Total participation time in this study is approximately 1 year and six months.

Study Type

Interventional

Enrollment (Actual)

156

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Greenbrae, California, United States
      • Los Banos, California, United States
      • San Diego, California, United States
      • Walnut Creek, California, United States
      • West Hills, California, United States
    • Colorado
      • Lakewood, Colorado, United States
      • Longmont, Colorado, United States
    • Florida
      • Boynton Beach, Florida, United States
      • Hialeah, Florida, United States
      • Jupiter, Florida, United States
    • Georgia
      • Dunwoody,, Georgia, United States
      • Gainesville, Georgia, United States
    • Hawaii
      • Honolulu, Hawaii, United States
    • Idaho
      • Idaho Falls, Idaho, United States
    • Illinois
      • Chicago, Illinois, United States
    • Iowa
      • Des Moines, Iowa, United States
      • Iowa City, Iowa, United States
    • Kentucky
      • Louisville, Kentucky, United States
    • Louisiana
      • Metarie, Louisiana, United States
    • Maine
      • Scarborough, Maine, United States
    • Maryland
      • Bethesda, Maryland, United States
    • Michigan
      • Detroit, Michigan, United States
    • Nebraska
      • Omaha, Nebraska, United States
    • New Mexico
      • Albuquerque, New Mexico, United States
    • New York
      • Mineola, New York, United States
      • West Haverstraw, New York, United States
    • North Carolina
      • Pinehurst, North Carolina, United States
    • Ohio
      • Cincinnati, Ohio, United States
    • Oregon
      • Portland, Oregon, United States
    • South Carolina
      • Aiken, South Carolina, United States
      • Greenville, South Carolina, United States
    • Tennessee
      • Brentwood, Tennessee, United States
    • Texas
      • Denton, Texas, United States
      • Houston, Texas, United States

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 70 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Is female and has not experienced menses for at least 5 years.
  • Has a Fasting Plasma Glucose level greater than or equal to 100 and less than 126 mg/dL or a 2-hour post-oral glucose tolerance test greater than or equal to 140 and less than or equal to 199 mg/dL at Screening.
  • Has a body mass index greater than or equal to 16 and less than or equal to 40 kg/m2 and weighs less than 300 pounds (approximately 136 kilograms).
  • Agrees to take daily supplements of Vitamin D (a minimum of 800 IU daily) and calcium (a minimum of 1000 mg daily) during the treatment and wash-out periods.
  • Has clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis [fasted for at least 8 hours]) within the reference range for the testing laboratory unless the results are deemed not clinically significant by the investigator or sponsor.
  • Is in good health as determined by the physician (ie, via medical history and physical examination) at Screening.

Exclusion Criteria:

  • Has a fasting triglyceride level greater than 500 mg/dL.
  • Has a hemoglobinopathy causing anemia or interfering with glycosylated hemoglobin assays.
  • Has an alanine transaminase level greater than or equal to 2.5 times the upper limit of normal, active liver disease or jaundice.
  • Has Vitamin D (25-OH-D) less than 20 ng/mL.
  • Has Baseline Bone Mineral Density defined as a T-score less than -2.0 at the total hip, spine, or femoral neck based on Caucasian reference values.
  • Has unexplained microscopic or macroscopic hematuria confirmed by repeat testing.
  • Has any of the following disorders:

    • Rheumatoid Arthritis
    • Thyroid (uncontrolled on thyroid replacement therapy), parathyroid, pituitary, nutritional, inflammatory, gastrointestinal, autoimmune, or renal or other disease known to affect bone metabolism.
    • A personal history of kidney stones.
  • Has a clinical history after age 45 of wrist, hip, or leg fractures.
  • Has a history of more than 1 asymptomatic vertebral deformity or any vertebral deformity attributed to osteoporosis.
  • Has a known history of drug abuse (defined as illicit drug use) or a known history of alcohol abuse within 2 years of Screening.
  • Has signs and/or symptoms of heart failure.
  • Is currently participating in another investigational study or has participated in an investigational study within the past 30 days or 5 half lives of the investigational product, whichever is longer.
  • Has any other serious disease or condition at screening or at randomization that might make it difficult to successfully manage and follow up with the subject according to the protocol.
  • Has a history of cancer, other than basal cell carcinoma or Stage 1 squamous cell carcinoma of the skin that has not been in remission for at least 5 years prior to the first dose of study drug.
  • Has a history of breast cancer.
  • Is taking or has ever taken pioglitazone or other Thiazolidinediones.
  • Has received or donated blood or blood products within 30 days preceding the Screening visit or plans to donate blood during the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
Other Names:
  • ACTOS®
Experimental: Pioglitazone
Pioglitazone 30 mg, tablets, orally, once daily for 4 weeks, then increased to Pioglitazone 45 mg, tablets, orally, once daily for up to 48 weeks.
Other Names:
  • ACTOS®

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percent Change From Baseline to Month 12 in Bone Mineral Density in the Total Proximal Femur by Dual-Energy-Ray Absorptiometry (DXA)
Time Frame: Baseline and Month 12.
The change in bone mineral density in the total proximal femur at month 12 relative to baseline. DXA is a means of measuring BMD through x-ray.
Baseline and Month 12.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percent Change From Month 12 to Month 18 in Bone Mineral Density in the Total Proximal Femur by DXA
Time Frame: Month 12 and Month 18.
The change in bone mineral density in the total proximal femur at month 18 relative to month 12. DXA is a means of measuring BMD through x-ray.
Month 12 and Month 18.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Fasting Plasma Glucose (FPG)
Time Frame: Baseline and Month 12; Month 12 and Month 18.
The change between the fasting plasma glucose value collected at each time frame indicated.
Baseline and Month 12; Month 12 and Month 18.
Number of Participants Who Converted to Type 2 Diabetes Mellitus (T2DM)
Time Frame: Up to 18 months.
Participants were considered to have converted to T2DM if there were ≥2 consecutive post-Baseline FPG measurements ≥126 mg/dL. Participants meeting criteria were tabulated and summarized by Study Period (Treatment and Follow-up). Conversion to T2DM during Treatment Period occurred if either both of the consecutive post-Baseline high FPG values, or the first of the 2 consecutive high values occurred on or before the first day off study drug. Conversion to T2DM occurred during the Follow-up Period if both consecutive high values occurred after at least 1 day after the Treatment Period.
Up to 18 months.
Number of Participants With Fracture
Time Frame: Up to 18 months.
Number of participants with confirmed (through an adjudication process) fractures during the study. Circumstances surrounding the fracture, available X-ray and other diagnostic results and healing status were collected for the adjudication process.
Up to 18 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2008

Primary Completion (Actual)

January 1, 2011

Study Completion (Actual)

February 1, 2011

Study Registration Dates

First Submitted

June 27, 2008

First Submitted That Met QC Criteria

July 1, 2008

First Posted (Estimate)

July 2, 2008

Study Record Updates

Last Update Posted (Estimate)

February 3, 2012

Last Update Submitted That Met QC Criteria

January 3, 2012

Last Verified

January 1, 2012

More Information

Terms related to this study

Other Study ID Numbers

  • AD-4833_402
  • U1111-1115-0660 (Registry Identifier: WHO)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe